NVCR NovoCure Limited Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

Settings

NVCR [NASD]

NovoCure Limited

Healthcare | Medical Appliances & Equipment | USA

financial highlights | statements

Index	-	P/E	-	EPS (ttm)	-1.11	Insider Own	1.90%	Shs Outstand	87.62M	Perf Week	2.76%
Market Cap	2.61B	Forward P/E	106.43	EPS next Y	0.28	Insider Trans	-41.82%	Shs Float	70.05M	Perf Month	21.88%
Income	-99.10M	PEG	-	EPS next Q	-0.16	Inst Own	55.20%	Short Float	4.17%	Perf Quarter	44.66%
Sales	194.30M	P/S	13.44	EPS this Y	29.30%	Inst Trans	12.34%	Short Ratio	3.11	Perf Half Y	64.19%
Book/sh	1.18	P/B	25.25	EPS next Y	145.20%	ROA	-23.70%	Target Price	31.20	Perf Year	156.90%
Cash/sh	2.47	P/C	12.07	EPS next 5Y	60.00%	ROE	-56.70%	52W Range	11.50 - 30.25	Perf YTD	47.52%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-41.40%	52W High	-1.49%	Beta	-
Dividend %	-	Quick Ratio	5.90	Sales past 5Y	-	Gross Margin	68.00%	52W Low	159.13%	ATR	1.01
Employees	495	Current Ratio	6.30	Sales Q/Q	49.30%	Oper. Margin	-19.90%	RSI (14)	69.92	Volatility	3.17% 3.50%
Optionable	Yes	Debt/Eq	1.41	EPS Q/Q	-11.60%	Profit Margin	-33.10%	Rel Volume	0.73	Prev Close	29.70
Shortable	Yes	LT Debt/Eq	1.41	Earnings	Apr 26 BMO	Payout	-	Avg Volume	938.85K	Price	29.80
Recom	1.60	SMA20	5.28%	SMA50	21.61%	SMA200	40.29%	Volume	682,715	Change	0.34%

Apr-18-18

Reiterated

Mizuho

Buy

$28 → $32

Feb-23-18

Reiterated

Mizuho

Buy

$25 → $28

May-24-17

Upgrade

Wells Fargo

Market Perform → Outperform

Jul-29-16

Reiterated

Wedbush

Outperform

$30 → $20

Jan-19-16

Initiated

Barclays

Underweight

$16

Dec-02-15

Initiated

Deutsche Bank

Hold

$28

Oct-27-15

Initiated

Wedbush

Outperform

Oct-27-15

Initiated

JP Morgan

Overweight

Oct-27-15

Initiated

JMP Securities

Mkt Outperform

$43

May-14-18 12:02PM	Best Growth Stock in May Simply Wall St.
May-11-18 11:46AM	Edited Transcript of NVCR earnings conference call or presentation 26-Apr-18 12:00pm GMT Thomson Reuters StreetEvents
Apr-26-18 04:53PM	This Explains Why NovoCure Is Surging Today Motley Fool +9.73%
11:55AM	NovoCure: 1Q Earnings Snapshot Associated Press
06:00AM	Novocure Reports First Quarter 2018 Financial Results and Provides Company Update Business Wire
06:00AM	Novocure Ltd. to Host Earnings Call ACCESSWIRE
Apr-25-18 11:10AM	NovoCure (NVCR) Shares March Higher, Can It Continue Zacks
Apr-19-18 08:00AM	Analysis: Positioning to Benefit within Verastem, DineEquity, Olin, Quantum, Kimco Realty, and NovoCure Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire +5.04%
07:10AM	Blog Exposure - NovoCure Announced Positive Top-line Results from STELLAR Trial Assessing TTFields in Mesothelioma ACCESSWIRE
Apr-18-18 08:31AM	NovoCure Limited (NVCR) Looks Good: Stock Adds 7.9% in Session Zacks
Apr-17-18 07:30AM	Novocure Reports Positive Top-line Results from STELLAR Phase 2 Pilot Trial in Mesothelioma Business Wire +7.89%
Apr-13-18 06:31PM	3 Top Healthcare Stocks to Buy in April Motley Fool
04:30PM	Data on Tumor Treating Fields to Be Presented at American Association for Cancer Research Annual Meeting Business Wire
Apr-03-18 12:23PM	Is NovoCure Limiteds (NASDAQ:NVCR) Balance Sheet A Threat To Its Future? Simply Wall St.
07:30AM	Novocure to Report First Quarter 2018 Financial Results Business Wire
Mar-20-18 09:14AM	NCCN Guidelines Recommend Optune in Combination with Temozolomide as a Category 1 Treatment for Newly Diagnosed Glioblastoma Business Wire
Mar-19-18 07:00AM	Wired News NovoCure Announced Data Presentations on Tumor Treating Fields at AACR Annual Meeting 2018 ACCESSWIRE
Mar-15-18 05:42PM	Analysts Expect Breakeven For NovoCure Limited (NASDAQ:NVCR) Simply Wall St.
07:30AM	Novocure Announces 35 Presentations on Tumor Treating Fields at the American Association for Cancer Research Annual Meeting 2018 Business Wire
Mar-08-18 04:21PM	Edited Transcript of NVCR earnings conference call or presentation 22-Feb-18 1:00pm GMT Thomson Reuters StreetEvents
Feb-26-18 07:03PM	Cramer Remix: It's time to investigate risky VIX-related ... CNBC Videos +7.25%
07:02PM	Tumor-treating biotech Novocure turns its attention to lu... CNBC Videos
06:59PM	Cramer Remix: It's time to investigate risky VIX-related trading products CNBC
Feb-22-18 07:30AM	NovoCure reports 4Q loss Associated Press
06:00AM	Novocure Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Company Update Business Wire
06:00AM	Novocure Ltd. to Host Earnings Call ACCESSWIRE
Feb-13-18 05:19PM	Who Really Owns NovoCure Limited (NASDAQ:NVCR)? Simply Wall St.
Feb-09-18 07:55AM	Report: Exploring Fundamental Drivers Behind Vector Group, NovoCure, ORBCOMM, Adamis Pharmaceuticals, Calumet Specialty Products Partners, and Lakeland New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Feb-07-18 04:01PM	Novocure Secures New $150 Million Non-Dilutive Term Loan Financing Business Wire
Feb-05-18 08:31AM	Minerva Neurosciences Names Remy Luthringer as Executive Chairman and William Doyle as Lead Independent Director GlobeNewswire
Feb-01-18 11:05AM	JAMA Oncology Publishes EF-14 Pivotal Trial Analysis Showing Optune Plus Temozolomide Improved Survival without Negatively Influencing Health-Related Quality of Life Compared to Temozolomide Alone in Newly Diagnosed GBM Patients Business Wire
Jan-16-18 06:15PM	Novocure Ltd (NVCR) CEO Asaf Danziger Sold $7.5 million of Shares GuruFocus.com
Jan-09-18 10:53AM	Here's Why NovoCure Popped 157% in 2017 Motley Fool
07:30AM	Novocure Announces Fourth Quarter and Full Year 2017 Operating Statistics and Preliminary Revenue Business Wire
Dec-21-17 06:25PM	Is NovoCure Limiteds (NASDAQ:NVCR) Balance Sheet Strong Enough To Weather A Storm? Simply Wall St.
06:00AM	3 Stocks That Could Put Amazon's Returns to Shame Motley Fool
Dec-20-17 07:30AM	Novocure to Participate in 36th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-19-17 11:05AM	JAMA Publishes Final Analysis of EF-14 Phase 3 Pivotal Trial of Optune® Together with Temozolomide Demonstrating Unprecedented Survival Results for Newly Diagnosed Glioblastoma Business Wire
Dec-18-17 07:37AM	Novocure Receives FDA IDE Approval for its PANOVA 3 Phase 3 Pivotal Clinical Trial in Advanced Pancreatic Cancer Business Wire
Dec-13-17 12:44PM	How Does NovoCure Limiteds (NASDAQ:NVCR) EPS Growth Stack Up Against Industry Performance? Simply Wall St.
Dec-11-17 08:17AM	Minerva Neurosciences Elects William Doyle and Hans Peter Hasler to Board of Directors GlobeNewswire
08:15AM	Minerva Neurosciences Elects William Doyle and Hans Peter Hasler to Board of Directors GlobeNewswire
Dec-07-17 02:25PM	ETFs with exposure to Novocure Ltd. : December 7, 2017 Capital Cube
Dec-04-17 11:28AM	Novocure Ltd. Value Analysis (NASDAQ:NVCR) : December 4, 2017 Capital Cube -6.89%
11:20AM	Is NovoCure Limited (NVCR) Undervalued? Simply Wall St.
Dec-01-17 07:30AM	Novocure Receives Reimbursement Approval for Optune® in Japan for the Treatment of Newly Diagnosed Glioblastoma Business Wire
07:13AM	Novocure Ltd. breached its 50 day moving average in a Bullish Manner : NVCR-US : December 1, 2017 Capital Cube
Nov-22-17 07:30AM	Novocure to Present at Two Upcoming Investor Conferences in December Business Wire
Nov-20-17 08:20AM	Investor Expectations to Drive Momentum within Vector Group, NovoCure, ORBCOMM, Ecolab, Bank of America, and Viking Therapeutics Discovering Underlying Factors of Influence GlobeNewswire
Nov-18-17 11:32AM	3 Top Medical Device Stocks to Buy Now Motley Fool
Nov-17-17 09:34AM	Estimating The Intrinsic Value Of NovoCure Limited (NVCR) Simply Wall St.
09:26AM	Novocure Shares Jump on Phase 3 Data Analysis -- Biotech Movers TheStreet.com
07:30AM	Patients Who Used Optune® More Than 90 Percent of the Time Had the Greatest Chance of Survival in Novocures EF-14 Trial: A Median Survival of 24.9 Months from Randomization and a Five-Year Survival of 29.3 Percent Business Wire
Nov-13-17 12:56PM	ETFs with exposure to Novocure Ltd. : November 13, 2017 Capital Cube
07:19AM	Novocure Announces 28 Presentations on Tumor Treating Fields from Externally Led Clinical Research and Analysis at 22nd Annual Meeting of the Society for Neuro-Oncology Business Wire
Nov-09-17 07:00AM	Novocure Announces 10 Presentations on Simulation Studies Aiming to Optimize Treatment Delivery of Tumor Treating Fields at 22nd Annual Meeting of the Society for Neuro-Oncology Business Wire
Nov-08-17 07:00AM	Novocure Announces 13 Preclinical Presentations Highlighting Data on Tumor Treating Fields Mechanism of Action at 22nd Annual Meeting of the Society for Neuro-Oncology Business Wire -6.13%
Nov-06-17 10:00AM	3 Stocks Changing the Future of Healthcare Motley Fool
07:00AM	Novocure Announces Six Clinical Presentations on Novocures Phase 3 Pivotal EF-14 Trial Data in Newly Diagnosed Glioblastoma at 22nd Annual Meeting of the Society for Neuro-Oncology Business Wire
Nov-01-17 12:16PM	Harry Boxers four stocks to watch this week MarketWatch
Oct-31-17 08:09AM	Novocure Ltd. breached its 50 day moving average in a Bullish Manner : NVCR-US : October 31, 2017 Capital Cube +6.14%
Oct-30-17 12:07PM	ETFs with exposure to Novocure Ltd. : October 30, 2017 Capital Cube
Oct-27-17 06:06PM	Edited Transcript of NVCR earnings conference call or presentation 26-Oct-17 12:00pm GMT Thomson Reuters StreetEvents +5.71%
09:18AM	Novocure Ltd. :NVCR-US: Earnings Analysis: Q3, 2017 By the Numbers : October 27, 2017 Capital Cube
Oct-26-17 06:45AM	NovoCure reports 3Q loss Associated Press
06:00AM	Novocure Reports Third Quarter 2017 Financial Results and Provides Company Update Business Wire
Oct-22-17 12:15PM	3 Healthcare Stocks for Your Radar Motley Fool
Oct-17-17 08:45AM	NovoCure (NVCR) Looks Good: Stock Adds 8.3% in Session Zacks
Oct-16-17 04:30PM	Why Rite Aid, Hudbay Minerals, and NovoCure Jumped Today Motley Fool +8.28%
07:30AM	Novocure Announces Data Presentations at the IASLC 18th World Conference on Lung Cancer Business Wire
Oct-03-17 11:53AM	Novocure Ltd. Value Analysis (NASDAQ:NVCR) : October 3, 2017 Capital Cube
Oct-02-17 08:22AM	Novocure Ltd. breached its 50 day moving average in a Bearish Manner : NVCR-US : October 2, 2017 Capital Cube
07:00AM	Novocure to Report Third Quarter 2017 Financial Results Business Wire
Sep-25-17 09:40AM	Intercept Spikes; Novocure Jumps on Phase 3 Data -Biotech Movers TheStreet.com
Sep-24-17 06:15PM	Combination of Optune® with Temozolomide Demonstrates Unprecedented Five-Year Survival for Newly Diagnosed Glioblastoma Patients Business Wire
Sep-22-17 07:00AM	Novocure Announces Data Presentations at the American Society for Radiation Oncologys 2017 Annual Meeting Business Wire
Sep-19-17 07:15AM	3 Innovation-Forward Healthcare Stocks to Buy Now Motley Fool
Sep-14-17 02:29PM	Dolby Laboratories is a stock to watch after Apples new iPhone launch MarketWatch
Sep-06-17 07:00AM	Novocure Announces Data Presentations at the ESMO 2017 Congress Business Wire
Sep-05-17 07:41AM	German Federal Joint Committee Announces Decision to Support a Clinical Trial to Study Optune® for the Treatment of Newly Diagnosed Glioblastoma Business Wire
Aug-28-17 08:23AM	If You Love Intuitive Surgical, You Should Check Out This Small-Cap Growth Stock Motley Fool
Aug-24-17 07:00AM	Novocure to Present at Two Upcoming Investor Conferences in September Business Wire
Aug-22-17 02:21PM	Edited Transcript of NVCR earnings conference call or presentation 27-Jul-17 12:00pm GMT Thomson Reuters StreetEvents
Aug-16-17 06:00AM	3 Stocks That Could Soar More Than Priceline Motley Fool
Aug-15-17 09:01PM	3 Game-Changing Small-Cap Healthcare Stocks Motley Fool
Aug-11-17 06:10PM	ETFs with exposure to Novocure Ltd. : August 11, 2017 Capital Cube
Aug-08-17 09:25AM	Novocure Announces National Reimbursement for Optune® in Austria Business Wire +5.23%
Aug-02-17 05:31PM	3 Exciting Biotechs Under $30: Novocure Is Revolutionizing Brain Cancer Treatment Motley Fool
07:00AM	Novocure to Present at the 2017 Wedbush PacGrow Healthcare Conference Business Wire
Jul-31-17 10:07AM	3 Hot Healthcare Stocks Under $30 Motley Fool
Jul-28-17 12:38PM	Novocure Ltd. :NVCR-US: Earnings Analysis: Q2, 2017 By the Numbers : July 28, 2017 Capital Cube
12:28AM	NovoCure reports 2Q loss Associated Press
Jul-27-17 06:15AM	Investor Network: Novocure Ltd. to Host Earnings Call ACCESSWIRE +5.97%
06:00AM	Novocure Reports Second Quarter 2017 Financial Results and Provides Company Update Business Wire
Jul-24-17 07:22AM	Novocure Announces a Phase 1b Clinical Trial to Evaluate the Safety of Marizomib and Temozolomide in Combination with Optune® as Adjuvant Therapy in Patients with Glioblastoma Business Wire
Jul-20-17 06:21PM	Many treatment options, most experimental, available to John McCain Reuters
Jul-18-17 08:16AM	These 2 Companies Have No Competition Motley Fool
Jul-13-17 06:07AM	The Fastest Growing Cancer Company You've Never Heard Of Motley Fool
Jul-12-17 08:47AM	NovoCure (NVCR) Jumps: Stock Rises 10.5% Zacks
08:20AM	Today's Research Reports on Stocks to Watch: Amicus Therapeutics, Inc. and NovoCure Ltd. Accesswire

Markets a wearable electric field device for treating glioblastoma brain cancer.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
LEUNG GABRIEL	Director	May 16	Option Exercise	3.44	100,000	344,000	100,000	May 17 04:18 PM
LEUNG GABRIEL	Director	May 16	Sale	28.77	40,000	1,150,800	60,000	May 17 04:18 PM
LEUNG GABRIEL	Director	May 15	Option Exercise	3.44	40,000	137,600	40,000	May 17 04:18 PM
LEUNG GABRIEL	Director	May 15	Sale	28.88	40,000	1,155,200	0	May 17 04:18 PM
GROENHUYSEN WILHELMUS CM	Chief Financial Officer	May 14	Sale	30.05	21,077	633,411	178,121	May 15 04:26 PM
GROENHUYSEN WILHELMUS CM	Chief Financial Officer	May 11	Sale	30.01	9,393	281,858	199,198	May 15 04:26 PM
Ambrogi Michael J.	Chief Operating Officer	May 01	Option Exercise	3.44	28,695	98,711	175,253	May 03 04:34 PM
Ambrogi Michael J.	Chief Operating Officer	May 01	Sale	27.40	60,000	1,644,000	146,558	May 03 04:34 PM
GROENHUYSEN WILHELMUS CM	Chief Financial Officer	May 01	Sale	27.58	30,470	840,363	208,591	May 03 04:30 PM
Ambrogi Michael J.	Chief Operating Officer	Apr 26	Option Exercise	3.44	20,000	68,800	166,558	Apr 30 05:56 PM
Ambrogi Michael J.	Chief Operating Officer	Apr 26	Sale	26.01	20,000	520,142	146,558	Apr 30 05:56 PM
Palti Yoram	Chief Technology Officer	Apr 26	Sale	26.09	20,966	547,013	1,161,054	Apr 30 05:03 PM
Palti Yoram	Chief Technology Officer	Apr 24	Sale	25.06	5,600	140,320	1,182,020	Apr 25 04:08 PM
Palti Yoram	Chief Technology Officer	Apr 23	Sale	25.07	30,000	751,962	1,187,620	Apr 25 04:08 PM
Palti Yoram	Chief Technology Officer	Apr 20	Sale	25.06	19,362	485,183	1,217,620	Apr 23 04:05 PM
Palti Yoram	Chief Technology Officer	Apr 19	Sale	24.93	30,000	748,042	1,236,982	Apr 23 04:05 PM
Ambrogi Michael J.	Chief Operating Officer	Apr 18	Option Exercise	3.44	20,000	68,800	166,558	Apr 19 04:54 PM
Kirson Eilon D.	Chief Science Officer	Apr 18	Option Exercise	3.44	147,825	508,518	116,451	Apr 20 04:53 PM
Kirson Eilon D.	Chief Science Officer	Apr 18	Sale	24.00	147,825	3,547,800	39,582	Apr 20 04:53 PM
Ambrogi Michael J.	Chief Operating Officer	Apr 18	Sale	24.00	20,000	480,000	146,558	Apr 19 04:54 PM
Palti Yoram	Chief Technology Officer	Apr 18	Sale	24.10	14,072	339,080	1,266,982	Apr 19 04:21 PM
Ambrogi Michael J.	Chief Operating Officer	Apr 17	Option Exercise	3.44	20,000	68,800	166,558	Apr 19 04:54 PM
Ambrogi Michael J.	Chief Operating Officer	Apr 17	Sale	22.06	20,000	441,240	146,558	Apr 19 04:54 PM
Palti Yoram	Chief Technology Officer	Apr 17	Sale	23.44	30,000	703,224	1,281,054	Apr 19 04:21 PM
Palti Yoram	Chief Technology Officer	Apr 04	Sale	19.89	30,000	596,754	1,311,054	Apr 05 04:17 PM
Palti Yoram	Chief Technology Officer	Apr 03	Sale	20.19	30,000	605,568	1,341,054	Apr 04 04:05 PM
Palti Yoram	Chief Technology Officer	Apr 02	Sale	20.46	30,000	613,861	1,371,054	Apr 04 04:05 PM
Palti Yoram	Chief Technology Officer	Mar 29	Sale	21.67	30,000	649,977	1,401,054	Apr 02 04:05 PM
Ambrogi Michael J.	Chief Operating Officer	Mar 19	Option Exercise	0.23	49,728	11,437	146,558	Mar 20 04:37 PM
Longsworth Todd Christopher	General Counsel	Feb 23	Sale	19.83	6,591	130,686	20,074	Feb 26 05:14 PM
Ambrogi Michael J.	Chief Operating Officer	Feb 23	Sale	19.83	8,458	167,705	96,830	Feb 26 05:13 PM
GROENHUYSEN WILHELMUS CM	Chief Financial Officer	Feb 23	Sale	19.83	13,351	264,724	239,061	Feb 26 05:09 PM
Longsworth Todd Christopher	General Counsel	Feb 22	Option Exercise	21.55	21,667	466,924	26,665	Feb 26 05:14 PM
Ambrogi Michael J.	Chief Operating Officer	Feb 22	Option Exercise	21.55	31,201	672,382	105,288	Feb 26 05:13 PM
Danziger Asaf	Chief Executive Officer	Feb 22	Option Exercise	21.55	53,334	1,149,348	410,124	Feb 26 05:11 PM
GROENHUYSEN WILHELMUS CM	Chief Financial Officer	Feb 22	Option Exercise	21.55	43,334	933,848	252,412	Feb 26 05:09 PM
Kirson Eilon D.	Chief Science Officer	Feb 22	Option Exercise	21.55	36,401	784,442	39,582	Feb 26 05:10 PM
Ambrogi Michael J.	Chief Operating Officer	Feb 06	Option Exercise	0.23	50,000	11,500	74,087	Feb 08 04:14 PM
Longsworth Todd Christopher	General Counsel	Jan 29	Option Exercise	6.72	11,630	78,154	16,628	Jan 31 04:29 PM
Longsworth Todd Christopher	General Counsel	Jan 29	Sale	24.00	11,630	279,120	4,998	Jan 31 04:29 PM
Danziger Asaf	Chief Executive Officer	Jan 29	Sale	24.02	13,974	335,588	356,790	Jan 31 04:22 PM
Danziger Asaf	Chief Executive Officer	Jan 25	Sale	22.43	6,456	144,840	370,764	Jan 26 04:14 PM
Danziger Asaf	Chief Executive Officer	Jan 24	Sale	22.17	10,600	235,007	377,220	Jan 25 04:26 PM
Danziger Asaf	Chief Executive Officer	Jan 23	Sale	22.03	10,248	225,794	387,820	Jan 25 04:26 PM
DOYLE WILLIAM F	Executive Chairman	Jan 22	Option Exercise	3.59	1,549	5,561	92,746	Jan 24 04:18 PM
Danziger Asaf	Chief Executive Officer	Jan 16	Sale	22.20	14,900	330,755	398,068	Jan 17 05:05 PM
Danziger Asaf	Chief Executive Officer	Jan 12	Sale	22.02	22,895	504,237	412,968	Jan 16 05:00 PM
Kirson Eilon D.	Chief Science Officer	Jan 11	Sale	22.00	25,320	557,126	3,181	Jan 16 05:01 PM
Danziger Asaf	Chief Executive Officer	Jan 11	Sale	22.35	313,525	7,007,503	435,863	Jan 16 05:00 PM
GROENHUYSEN WILHELMUS CM	Chief Financial Officer	Jan 09	Sale	21.02	31,132	654,376	209,078	Jan 10 04:11 PM
GROENHUYSEN WILHELMUS CM	Chief Financial Officer	Jan 04	Sale	21.03	26,264	552,314	239,900	Jan 05 04:06 PM
GROENHUYSEN WILHELMUS CM	Chief Financial Officer	Jan 03	Sale	21.00	2,604	54,689	266,164	Jan 05 04:06 PM
Palti Yoram	Chief Technology Officer	Nov 13	Sale	17.13	30,000	513,870	1,431,054	Nov 14 04:25 PM
Palti Yoram	Chief Technology Officer	Nov 10	Sale	17.61	30,000	528,150	1,461,054	Nov 13 04:36 PM
Palti Yoram	Chief Technology Officer	Nov 09	Sale	18.25	30,000	547,433	1,491,054	Nov 13 04:36 PM
Palti Yoram	Chief Technology Officer	Nov 08	Sale	19.61	30,000	588,249	1,521,054	Nov 13 04:36 PM
Palti Yoram	Chief Technology Officer	Nov 07	Sale	20.42	30,000	612,520	1,551,054	Nov 08 04:17 PM
Palti Yoram	Chief Technology Officer	Nov 06	Sale	21.71	30,000	651,240	1,581,054	Nov 08 04:17 PM
Kirson Eilon D.	Chief Science Officer	Nov 06	Sale	22.00	9,100	200,200	28,501	Nov 08 04:15 PM
Danziger Asaf	Chief Executive Officer	Nov 06	Sale	22.00	6,919	152,218	749,105	Nov 08 04:14 PM
Palti Yoram	Chief Technology Officer	Nov 03	Sale	21.66	30,000	649,680	1,611,054	Nov 06 04:22 PM
Kirson Eilon D.	Chief Science Officer	Nov 03	Sale	22.00	3,100	68,200	37,601	Nov 06 04:18 PM
Ambrogi Michael J.	Chief Operating Officer	Nov 03	Sale	22.00	900	19,800	24,087	Nov 06 04:17 PM
Danziger Asaf	Chief Executive Officer	Nov 03	Sale	22.00	2,300	50,600	756,024	Nov 06 04:15 PM
Palti Yoram	Chief Technology Officer	Nov 02	Sale	21.78	30,000	653,520	1,641,054	Nov 06 04:22 PM
Kirson Eilon D.	Chief Science Officer	Nov 02	Sale	22.00	300	6,600	40,701	Nov 06 04:18 PM
Ambrogi Michael J.	Chief Operating Officer	Nov 02	Sale	22.00	300	6,600	24,987	Nov 06 04:17 PM
Danziger Asaf	Chief Executive Officer	Nov 01	Sale	22.01	15,716	345,870	758,324	Nov 02 04:20 PM
Kirson Eilon D.	Chief Science Officer	Nov 01	Sale	22.01	22,119	486,810	41,001	Nov 02 04:22 PM
Ambrogi Michael J.	Chief Operating Officer	Nov 01	Sale	22.01	24,227	533,164	25,287	Nov 02 04:19 PM
Danziger Asaf	Chief Executive Officer	Oct 31	Sale	22.00	150	3,300	774,040	Nov 02 04:20 PM
Kirson Eilon D.	Chief Science Officer	Oct 31	Sale	22.00	150	3,300	63,120	Nov 02 04:22 PM
Ambrogi Michael J.	Chief Operating Officer	Oct 31	Sale	22.00	100	2,200	49,514	Nov 02 04:19 PM
Danziger Asaf	Chief Executive Officer	Sep 25	Sale	22.05	900	19,845	774,190	Sep 27 04:18 PM
Danziger Asaf	Chief Executive Officer	Sep 14	Sale	22.00	1,772	38,984	775,090	Sep 15 04:05 PM
Danziger Asaf	Chief Executive Officer	Sep 13	Sale	22.01	35,500	781,518	776,862	Sep 15 04:05 PM
Danziger Asaf	Chief Executive Officer	Jul 14	Option Exercise	0.38	354,780	134,816	812,362	Jul 18 04:48 PM
Danziger Asaf	Chief Executive Officer	Jul 11	Sale	19.95	7,383	147,325	457,582	Jul 13 04:14 PM
Danziger Asaf	Chief Executive Officer	Jul 10	Sale	18.08	203,900	3,685,900	464,965	Jul 11 04:22 PM
Danziger Asaf	Chief Executive Officer	Jul 07	Sale	18.03	70,459	1,270,658	668,865	Jul 11 04:22 PM
Danziger Asaf	Chief Executive Officer	Jul 06	Sale	18.09	5,050	91,344	739,324	Jul 07 04:33 PM
Danziger Asaf	Chief Executive Officer	Jul 05	Sale	18.14	155,088	2,813,917	744,374	Jul 07 04:33 PM
Pomona Capital VII, L.P.	10% Owner	Jun 26	Sale	17.46	99,341	1,734,186	2,741,925	Jun 27 04:11 PM
Pomona Capital VII, L.P.	10% Owner	Jun 23	Sale	17.34	973,191	16,872,894	2,772,870	Jun 27 04:11 PM
Kirson Eilon D.	Chief Science Officer	Jun 21	Sale	16.78	66,361	1,113,206	222,722	Jun 22 04:29 PM
Kirson Eilon D.	Chief Science Officer	Jun 19	Sale	15.06	15,000	225,885	289,083	Jun 21 04:19 PM
Danziger Asaf	Chief Executive Officer	Jun 19	Sale	15.51	124,720	1,934,906	896,917	Jun 21 04:17 PM
Danziger Asaf	Chief Executive Officer	Jun 16	Sale	15.02	9,212	138,346	1,021,637	Jun 19 04:31 PM
Danziger Asaf	Chief Executive Officer	Jun 15	Sale	15.19	33,245	504,892	1,030,849	Jun 19 04:31 PM
DOYLE WILLIAM F	Director	Jun 14	Option Exercise	3.59	6,498	23,328	91,197	Jun 15 04:23 PM
Danziger Asaf	Chief Executive Officer	Jun 14	Sale	15.01	5,402	81,068	1,064,094	Jun 15 04:17 PM
Kirson Eilon D.	Chief Science Officer	Jun 13	Sale	15.01	9,044	135,769	304,083	Jun 15 04:28 PM
Danziger Asaf	Chief Executive Officer	Jun 13	Sale	15.23	88,700	1,351,078	1,069,496	Jun 15 04:17 PM
Danziger Asaf	Chief Executive Officer	Jun 12	Sale	15.09	5,100	76,934	1,158,196	Jun 13 06:35 PM
Kirson Eilon D.	Chief Science Officer	Jun 12	Sale	15.08	5,956	89,828	313,127	Jun 13 06:19 PM
Danziger Asaf	Chief Executive Officer	Jun 09	Sale	15.13	175,501	2,654,979	1,163,296	Jun 13 06:35 PM
Kirson Eilon D.	Chief Science Officer	Jun 09	Sale	15.02	15,000	225,225	319,083	Jun 13 06:19 PM
Palti Yoram	Chief Technology Officer	Jun 05	Sale	13.82	3,825	52,842	0	Jun 06 05:17 PM
Palti Yoram	Chief Technology Officer	Jun 02	Sale	13.49	4,000	53,956	3,825	Jun 05 04:19 PM
Palti Yoram	Chief Technology Officer	Jun 01	Sale	13.05	4,000	52,184	7,825	Jun 05 04:19 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience